The dose-response model predicts that among all antigens, MSP3α C-term and MSP9 N-term need the lowest levels of specific antibodies to show an association with 50% reduction in symptomatic infections, followed by CyRPA, EBP, RBP1a, RBP2b, and RBP2-P2 (Figure 6a–c; Figure 6—figure supplement 1). Here, RBP2 is linked to infection.